Alzamend Receives FDA 'Study May Proceed' Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

ATLANTA: Alzamend Neuro, Inc., ('Alzamend') a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ('Alzheimer's'), bipolar disorder ('BD'), major depressive disorder ('MDD') and post-traumatic [...]